|

Selective Removal of Endometriotic Lesions Using CUSA Clarity in Ovarian Endometriomas

RECRUITINGSponsored by Kanazawa University
Actively Recruiting
SponsorKanazawa University
Started2025-01-30
Est. completion2027-03-31
Eligibility
Age20 Years+
SexFEMALE
Healthy vol.Accepted

Summary

This study aims to evaluate the feasibility and tissue selectivity of a novel surgical technology, the Cavitron Ultrasonic Surgical Aspirator (CUSA) Clarity, in the management of ovarian endometriomas. Ovarian endometriomas are cysts caused by endometriosis that can damage ovarian reserve when treated by conventional surgery. In this study, ovarian cyst wall specimens are examined ex vivo using different Tissue Select settings of the CUSA device. Histopathological analyses are performed to determine whether endometriotic epithelium can be selectively removed while preserving normal ovarian tissue. The findings may contribute to developing fertility-preserving surgical approaches for women with endometriomas.

Eligibility

Age: 20 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Female patients diagnosed with ovarian endometrioma who undergo surgical treatment (cystectomy or adnexectomy) at Kanazawa University Hospital between January 1, 2025, and March 31, 2027.
* Written informed consent obtained prior to study participation.
* Age ≥ 20 years at the time of consent.
* For patients with previously stored endometrioma specimens under a broad consent, additional written consent for participation in this study will be obtained.

Exclusion Criteria:

* Patients with suspected malignancy based on preoperative imaging.
* Patients judged by the attending physician to be unsuitable for participation in this study for any reason.

Conditions3

CancerEndometriosisOvarian Endometrioma

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.